IL-17 inhibits the accumulation of myeloid-derived suppressor cells in breast cancer via activating STAT3

International Immunopharmacology

Volumn 59, Issue , 2018, Pages 148-156

  Ma, Min ^a   Huang, Wei ^a   Kong, Dehua ^a  

^a Gaochun Hospital of Nanjing   (China)

Author keywords

Breast Cancer; IL 17; MDSC; STAT3

Indexed keywords

INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 17; STAT3 PROTEIN; VASCULOTROPIN A;

ANIMAL; APOPTOSIS; BAGG ALBINO MOUSE; BLOOD; BREAST TUMOR; CELL DIFFERENTIATION; CELL PROLIFERATION; CYTOLOGY; DRUG EFFECT; FEMALE; GENETICS; HUMAN; METABOLISM; MIDDLE AGED; MYELOID-DERIVED SUPPRESSOR CELL; PATHOLOGY;

ANIMALS; APOPTOSIS; BREAST NEOPLASMS; CELL DIFFERENTIATION; CELL PROLIFERATION; FEMALE; HUMANS; INTERLEUKIN-17; MICE, INBRED BALB C; MIDDLE AGED; MYELOID-DERIVED SUPPRESSOR CELLS; NITRIC OXIDE SYNTHASE TYPE II; STAT3 TRANSCRIPTION FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 85045078058     PISSN: 15675769     EISSN: 18781705     Source Type: Journal    
DOI: 10.1016/j.intimp.2018.04.013     Document Type: Article

References (38)

1. Ferlay, J., Soerjomataram, I., Dikshit, R. et al., Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012[J]. Int. J. Cancer, 136(5), 2015, E359.
2. Siegel, R., Desantis, C., Virgo, K. et al., Cancer treatment and survivorship statistics, 2012.[J]. CA Cancer J. Clin., 62(4), 2012, 220.
3. Rossi, S., Schinzari, G., Basso, M. et al., Maintenance hormonal and chemotherapy treatment in metastatic breast cancer: a systematic review.[J]. Future Oncol. 12:10 (2016), 1299–1307.
4. Cinzia, G., Francesca, C., Salvatore, P. et al., Leptin as a mediator of tumor-stromal interactions promotes breast cancer stem cell activity:[J]. Oncotarget 7:2 (2016), 1262–1275.
5. Tan, X.F., Xia, F., Long-term fatigue state in postoperative patients with breast cancer[J]. Chin. J. Cancer Res. 26:1 (2014), 12–16.
6. Miossec, P., Korn, T., Kuchroo, V.K., Mechanisms of desease: Interleukin-17 and type 17 helper T cells[J]. N. Engl. J. Med. 361:9 (2009), 888–898.
7. Kryczek, I., Banerjee, M., Cheng, P. et al., Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments [J]. Blood, 114(6), 2009, 1141.
8. Korn, T., Bettelli, E., Oukka, M. et al., IL-17 and Th17 cells.[J]. Annu. Rev. Immunol. 27:1 (2009), 485–517.
9. Zhang, B., Rong, G., Wei, H. et al., The prevalence of Th17 cells in patients with gastric cancer[J]. Biochem. Biophys. Res. Commun. 374:3 (2008), 533–537.
10. Gu, C., Wu, L., Li, X., IL-17 family: cytokines, receptors and signaling.[J]. Cytokine 64:2 (2013), 477–485.
11. Najjar, Y.G., Finke, J.H., Clinical perspectives on targeting of myeloid derived suppressor cells in the treatment of cancer[J]. Front. Oncol., 3, 2013, 49.
12. Drake, C.G., Lipson, E.J., Brahmer, J.R., Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer[J]. Nat. Rev. Clin. Oncol., 11(1), 2014, 24.
13. Talmadge, J.E., Gabrilovich, D.I., History of myeloid-derived suppressor cells.[J]. Nat. Rev. Cancer, 13(10), 2013, 739.
14. Gabrilovich, D.I., Nagaraj, S., Myeloid-derived suppressor cells as regulators of the immune system.[J]. Nat. Rev. Immunol., 9(3), 2009, 162.
15. Solito, S., Falisi, E., Diazmontero, C.M. et al., A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells.[J]. Blood 118:8 (2011), 2254–2265.
16. Raychaudhuri, B., Rayman, P., Ireland, J. et al., Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma[J]. Neuro-Oncology, 13(6), 2011, 591.
17. Gabitass, R.F., Annels, N.E., Stocken, D.D. et al., Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13.[J]. Cancer Immunol. Immunother., 60(10), 2011, 1419.
18. Solito, S., Falisi, E., Diazmontero, C.M. et al., A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells.[J]. Blood 118:8 (2011), 2254–2265.
19. Wang, L., Wang, X., Zhang, S., A protective role of heme-regulated eIF2α kinase in cadmium-induced toxicity in erythroid cells[J]. Food Chem. Toxicol., 62, 2013, 880.
20. Zou, Z., Wu, L., Ding, H. et al., MicroRNA-30a sensitizes tumor cells to cis-platinum via suppressing Beclin 1-mediated autophagy[J]. J. Biol. Chem. 287:6 (2012), 4148–4156.
21. Yin, Y., Zhang, B., Wang W, et al. miR-204-5p inhibits proliferation and invasion and enhances chemotherapeutic sensitivity of colorectal cancer cells by downregulating RAB22A[J]. Clin. Cancer Res., 20(23), 2014, 6187.
22. Drake, C.G., Lipson, E.J., Brahmer, J.R., Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer[J]. Nat. Rev. Clin. Oncol., 11(1), 2014, 24.
23. Talmadge, J.E., Gabrilovich, D.I., History of myeloid-derived suppressor cells.[J]. Nat. Rev. Cancer, 13(10), 2013, 739.
24. Ostrand-Rosenberg, S., Sinha, P., Myeloid-derived suppressor cells: linking inflammation and cancer. J. Immunol. 182:8 (2009), 4499–4506.
25. Najjar, Y.G., Finke, J.H., Clinical perspectives on targeting of myeloid derived suppressor cells in the treatment of cancer[J]. Front. Oncol., 3, 2013, 49.
26. Alizadeh, D., Trad, M., Hanke, N.T. et al., Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast cancer.[J]. Cancer Res. 74:1 (2014), 104–118.
27. Bayne, L.J., Beatty, G.L., Jhala, N. et al., Tumor-derived granulocyte-macrophage colony stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer[J]. Cancer Cell 21:6 (2012), 822–835.
28. Khaled, Y.S., Ammori, B.J., Elkord, E., Myeloid-derived suppressor cells in cancer: recent progress and prospects[J]. Immunol. Cell Biol. 91:8 (2013), 493–502.
29. Numasaki, M., Fukushi, J., Ono, M. et al., Interleukin-17 promotes angiogenesis and tumor growth.[J]. Blood, 101(7), 2003, 2620.
30. Kryczek, I., Banerjee, M., Cheng, P. et al., Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments[J]. Blood, 114(6), 2009, 1141.
31. Benchetrit, F., Ciree, A., Vives, V. et al., Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism.[J]. Blood, 99(6), 2002, 2114.
32. Sparna, T., Rétey, J., Schmich, K. et al., Genome-wide comparison between IL-17 and combined TNF-alpha/IL-17 induced genes in primary murine hepatocytes[J]. BMC Genomics, 11(1), 2010, 226.
33. Gu, F.M., Li, Q.L., Gao, Q. et al., IL-17 induces AKT-dependent IL-6/JAK2/STAT3 activation and tumor progression in hepatocellular carcinoma[J]. Mol. Cancer, 10(1), 2011, 150.
34. Trikha, P., Iii, W.E.C., Signaling pathways involved in MDSC regulation[J]. Biochim. Biophys. Acta 1846:1 (2014), 55–65.
35. Yu, H., Pardoll, D., Jove, R., STATs in cancer inflammation and immunity: a leading role for STAT3.[J]. Nat. Rev. Cancer 9:11 (2009), 798–809.
36. Nefedova, Y., Nagaraj, S., Rosenbauer, A. et al., Regulation of dendritic cell differentiation and antitumor immune response in cancer by pharmacologic-selective inhibition of the janus-activated kinase 2/signal transducers and activators of transcription 3 pathway.[J]. Cancer Res. 65:20 (2005), 9525–9535.
37. Kusmartsev, S., Nefedova, Y., Yoder, D. et al., Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species.[J]. J. Immunol. 172:2 (2004), 989–999.
38. Thomas-Schoemann, A., Batteux, F., Mongaret, C. et al., Arsenic trioxide exerts antitumor activity through regulatory T cell depletion mediated by oxidative stress in a murine model of colon cancer[J]. J. Immunol. 189:11 (2012), 5171–5177.